MHC-HM407T-100μg / 询价
MHC-HM407T-500μg / 询价
MHC-HM407T-500μgx2 / 询价
- 客服电话
- 技术支持
Human HLA-A*02:01&B2M&AFP (FMNKFIYEI) Tetramer Protein
Recombinant Human HLA-A*02:01&B2M&AFP (FMNKFIYEI) Tetramer Protein is expressed from HEK293 with His tag and Avi tag at the C-Terminus, tetramer is assembled by biotinylated monomer and streptavidin.It contains Gly25-Thr305(HLA-A*02:01),Ile21-Met119(B2M) and FMNKFIYEI peptide [Accession | A0A140T913(HLA-A*02:01)&P61769(B2M)&FMNKFIYEI ].
The protein has a predicted MW of 258 kDa. Due to glycosylation, the protein migrates to 260-265 kDa under Non reducing (N) condition based on Bis-Tris PAGE result.
> 95% as determined by Bis-Tris PAGE
> 95% as determined by HPLC
Less than 1EU per ug by the LAL method.
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
-20 to -80°C for 12 months as supplied from date of receipt.
-80°C for 3 months after reconstitution.
Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Human HLA-A*02:01&B2M&AFP (FMNKFIYEI) Tetramer on Bis-Tris PAGE under Non reducing (N) condition. The purity is greater than 95%.
The purity of Human HLA-A*02:01&B2M&AFP (FMNKFIYEI) Tetramer is greater than 95% as determined by SEC-HPLC.
Immobilized Human HLA-A*02:01&B2M&AFP (FMNKFIYEI) Tetramer, His Tag at 1μg/ml (100μl/well) on the plate. Dose response curve for Anti-HLA-A*02:01&B2M&AFP (FMNKFIYEI) Antibody, hFc Tag with the EC50 of 3.9ng/ml determined by ELISA (QC Test).
Immobilized HLA-A*02:01&B2M&AFP (FMNKFIYEI) TCR at 2μg/ml (100μl/well) on the plate. Dose response curve for Human HLA-A*02:01&B2M&AFP (FMNKFIYEI) Tetramer, His Tag with the EC50 of 26.6ng/ml determined by ELISA.
Human HLA-A*02:01&B2M&AFP (FMNKFIEl) Tetramer, His Tag captured on CM5 Chip via Anti-His Antibody can bind HLA-A*02:01&B2M&AFP (FMNKFIYEI) TCR with an affinity constant of 0.111 μM as determined in SPR assay (Biacore T200).
Alpha-fetoprotein (AFP), a specific liver cancer marker, T cells expressing AFP-CAR selectively degranulated, released cytokines, and lysed liver cancer cells that were HLA-A*02:01 /AFP while sparing cells from multiple tissue types that were negative for either expressed proteins.CAR T-cell immunotherapy targeting intracellular/secreted solid tumor antigens can elicit a potent antitumor response.
Alpha-fetoprotein; Alpha-1-fetoprotein; Alpha-feto; AFP; HPAFP; AFPD; FETA; MHC
(1) Liu H, Xu Y, Xiang J, Long L, Green S, Yang Z, Zimdahl B, Lu J, Cheng N, Horan LH, Liu B, Yan S, Wang P, Diaz J, Jin L, Nakano Y, Morales JF, Zhang P, Liu LX, Staley BK, Priceman SJ, Brown CE, Forman SJ, Chan VW, Liu C. Targeting Alpha-Fetoprotein (AFP)-MHC Complex with CAR T-Cell Therapy for Liver Cancer. Clin Cancer Res. 2017 Jan 15;23(2):478-488. doi: 10.1158/1078-0432.CCR-16-1203. Epub 2016 Aug 17. PMID: 27535982.
